News
BellaSeno Starts Two Clinical Trials of its Resorbable Breast and Chest Implants
— Resorbable implants to treat pectus excavatum and silicone breast implant revision / congenital defect correction
— First patients treated in Australia
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced the start of two clinical trials of its products in Australia, which are sponsored by its Australian subsidiary BellaSeno Pty. Already, recruiting has started in Brisbane, Australia.
ELITechGroup and InfanDx AG to Collaborate on the Development and Manufacturing of HypoxE® Neonatal Care Test for Clinical Laboratories
— HypoxE® Test allows for the early detection of Hypoxic-Ischemic Encephalopathy (HIE) caused by lack of oxygen during birth
— ELITechGroup to provide contract development and manufacturing services for HypoxE® IVD Tests designed for Selectra Pro family of clinical chemistry analyzers
ELITechGroup and InfanDx AG today announced at the ongoing 2022 AACC Annual Scientific Meeting & Clinical Lab Expo in Chicago, IL, USA, the signing of a Memorandum of Understanding (MoU) to collaborate on the development and manufacturing of InfanDx’ HypoxE® Test for ELITechGroup’s family of Selectra Pro clinical chemistry analyzers. The parties intend to enter into a formal collaboration agreement once the biomarkers targeted by InfanDx’ HypoxE® Test are validated in patients from the recently closed BANON cohort study. This final validation is expected by the end of Q3-2022.
ImmunOs Therapeutics Raises $74 Million Series B Financing Round
– New investors Samsara, Lightspeed, Gimv, and Mission BioCapital further strengthen investor base and expand transatlantic footprint
– Company establishes U.S. subsidiary to accelerate international operations
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL Capital, PEAK6 Strategic Capital, and Fiscus Financial, as well as existing investors Pfizer Ventures, BioMed Partners, and Schroder Adveq. Read more…
Dopavision Appoints Mark S. Wuttke, Ph.D., as Chief Executive Officer
– Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities
– Company recently initiated clinical trial of novel digital therapeutic for childhood myopia
Dopavision, a company pioneering the development of digital therapeutics, today announced that Mark S. Wuttke, Ph.D., has been appointed as the Company´s Chief Executive Officer. He succeeds Dopavision´s co-founder and previous Managing Director Stefan Zundel, who will remain on Dopavision´s advisory board and continue to advise the Company.
Mark Wuttke brings more than two decades of healthcare business expertise, in particular, comprehensive experience in the development and commercialization of ophthalmology products at Novartis, a global leader in eye health. He also has a strong track record in corporate strategy and branding. Read more…